Boston Partners lifted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 15.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,890,966 shares of the biopharmaceutical company's stock after buying an additional 529,575 shares during the quarter. Boston Partners owned 0.19% of Bristol-Myers Squibb worth $220,088,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Wealthspire Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 0.6% during the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after buying an additional 170 shares during the last quarter. Edmp Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.4% during the 4th quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock worth $2,353,000 after buying an additional 171 shares during the last quarter. Trust Point Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.9% during the 4th quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock worth $533,000 after buying an additional 172 shares during the last quarter. Bedel Financial Consulting Inc. boosted its stake in shares of Bristol-Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock worth $340,000 after buying an additional 175 shares during the last quarter. Finally, Horst & Graben Wealth Management LLC boosted its stake in shares of Bristol-Myers Squibb by 2.4% during the 4th quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock worth $426,000 after buying an additional 179 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Bristol-Myers Squibb
In related news, EVP Samit Hirawat bought 1,823 shares of the business's stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.09% of the stock is currently owned by insiders.
Bristol-Myers Squibb Stock Performance
Shares of BMY traded up $0.64 during mid-day trading on Friday, hitting $61.06. 25,864,960 shares of the company's stock were exchanged, compared to its average volume of 12,181,935. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The stock's 50-day simple moving average is $58.17 and its 200-day simple moving average is $55.93. The firm has a market cap of $123.92 billion, a price-to-earnings ratio of -13.82, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.
Bristol-Myers Squibb Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 4.06%. Bristol-Myers Squibb's dividend payout ratio (DPR) is -56.11%.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on BMY shares. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Bank of America reiterated a "neutral" rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Truist Financial raised their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Finally, Citigroup raised their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $57.86.
Get Our Latest Stock Analysis on BMY
Bristol-Myers Squibb Company Profile
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
